On November 2, 2021 ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, reported that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in four upcoming virtual investor conferences (Press release, ALX Oncology, NOV 2, 2021, View Source [SID1234594088]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Credit Suisse 30th Annual Healthcare Conference
Format: Fireside chat with analyst, Tiago Fauth
Date: Monday, November 8
Time: 2:40 PM Eastern Time
Webcast link: Available here

Stifel 2021 Healthcare Conference
Format: Fireside chat with analyst, Bradley Canino
Date: Tuesday, November 16
Time: 10:00 AM Eastern Time
Webcast link: Available here

Jefferies 2021 London Healthcare Conference
Format: Fireside chat with analyst, Michael Yee
Date: Thursday, November 18 – Friday, November 19
Webcast link: Available here

Piper Sandler 33rd Virtual Healthcare Conference
Format: Fireside chat with analyst, Christopher Raymond
Date: Monday, November 22
Time: 10:00 AM Eastern Time
Webcast link: Will be made available shortly

A webcast of the fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the fireside chat dates.

On November 2, 2021 Primmune Therapeutics reported interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer (Press release, Primmune Therapeutics, NOV 2, 2021, View Source [SID1234594083]). This double blind, placebo-controlled Phase 1 study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of PRTX007 in single- and multiple-ascending dose cohorts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PRTX007 is Primmune’s lead TherAjuvant, a reference to its combination of therapeutic and adjuvant mechanisms of action. PRTX007 is designed to provide immediate benefit to patients through controlled stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses. PRTX007 uniquely engages TLR7 and targeted immune cells without exacerbating inflammation, a critical feature in treating respiratory viral infections. More broadly, PRTX007 and other TherAjuvants differ from therapeutic vaccines in that the source of the antigens presented to the patient’s immune system come from the treated pathology. Additionally, TherAjuvants differ from most small molecule approaches in that they target the patient’s immune system and not tumor cells or virally encoded targets.

"PRTX007 is performing as expected and is echoing the pharmacology, safety and tolerability data that we generated in human peripheral blood mononuclear cells, in primate pharmacology studies and in 2-week rodent and primate GLP safety studies," said James Appleman, Ph.D., Co-founder and Chief Scientific Officer at Primmune Therapeutics. "PRTX007 was derived from Primmune’s extensive TLR7 agonist discovery program and could potentially have utility both in treatment and prophylaxis, serving as a first-line defense against SARS-CoV-2, its mutants, and other future novel pathogens."

The Phase 1 study of PRTX007 has completed the single-ascending dose cohorts with doses ranging from 50 mg – 600 mg. PRTX007 was safe and well tolerated with no dose modifications or treatment discontinuations. In general, systemic drug exposure increased proportionally with PRTX007 dose. The expected pattern of increased expression of interferon stimulated genes (ISGs) and increased levels of specific circulating chemokines and cytokines signaling an induction of innate immunity was observed.

In multiple-ascending dose (MAD) cohorts, initial PK data showed consistency for the 300 mg group and was comparable at day 1 and day 13 exposures. Additional data on subsequent MAD cohorts, induction of ISGs mRNA expression and chemokine/cytokines are expected by the end of 2021.

"PRTX007 has thus far demonstrated a benign safety and tolerability profile with increasing dose-dependent exposure; building our confidence as we rapidly advance towards clinical trials for acute viral diseases and cancer," Curtis Scribner, M.D., Chief Medical Officer at Primmune Therapeutics.

On November 2, 2021 Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported that Chief Executive Officer, Bill Newell, will participate in three upcoming virtual investor conferences (Press release, Sutro Biopharma, NOV 2, 2021, View Source [SID1234594082]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Credit Suisse 30th Annual Healthcare Conference
Format: Virtual Presentation
Date: Wednesday, Nov. 10, 2021
Time: 4:20 p.m. EST / 1:20 p.m. PST

Stifel Virtual Healthcare Conference
Format: Virtual Presentation
Date: Monday, Nov. 15, 2021
Time: 1:20 p.m. EST / 10:20 a.m. PST

Jefferies London Healthcare Conference
Format: Pre-recorded Fireside Chat
Date: Thursday, Nov. 18, 2021
Time: 3:00 a.m. EST / 12:00 a.m. PST / 8:00 a.m. GMT

Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company’s website at www.sutrobio.com. Archived replays of the webcasts will be available on the company’s website for approximately 30 days following each live presentation.

On November 2, 2021 Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, reported the upcoming presentations by members of its management team at several industry and scientific conferences during November 2021 (Press release, ImmuneTune, NOV 2, 2021, View Source [SID1234594081]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are looking forward to presenting our platform of synthetic DNA vaccines to an audience of investors, pharma and biotech companies, and scientists and investigators," said Sijme Zeilemaker, CEO of Immunetune. "With our lead program NeoVAC, a personalized neoantigen cancer vaccine, moving towards the clinic in 2022, it is a great opportunity to showcase our unique differentiation and explore collaborations with leaders in this field."

Upcoming conferences:

Drug Discovery Strategic Summit, November 4 – 5, Amsterdam, the Netherlands

CEO Sijme Zeilemaker will be presenting on November 4th, 9:50 – 10:10 AM, on "Next-generation DNA vaccines targeting cancer and infectious diseases".

LSX Investival Showcase, November 8 – 15, Virtual / London, UK

CEO Sijme Zeilemaker will be participating virtually and in person on November 15th in London. Please reach out to [email protected] if you would like to set up a meeting within our scope of investors and pharma/biotech collaborations.

Festival of Biologics / World Immunotherapy Congress, November 9 – 11, Basel, Switzerland

CEO Sijme Zeilemaker will be presenting on November 9th, 5:50 – 6:10 PM, in the Innate & Adaptive Checkpoint Inhibition track on "Neoantigen cancer vaccines based on synthetic linear DNA with a pyroptotic adjuvant synergize with checkpoint inhibitors".

Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, November 10 – 14, Virtual / Washington, D.C., US

CSO Jeroen van Bergen will be presenting the poster titled "Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity". Abstracts can be accessed on the SITC (Free SITC Whitepaper) website once the conference begins on November 9th; posters will be presented on November 12 and 13.

On November 2, 2021 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that it will host a conference call and webcast on Tuesday, November 9, 2021 at 8:00 a.m. ET to report financial results for the third quarter ended September 30, 2021 and provide business updates (Press release, Mersana Therapeutics, NOV 2, 2021, https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-host-conference-call-announcing-third-2 [SID1234594075]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 2116349. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.